Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis. (nature.com)

Authors: Kong W … Zhang J Journal: Nature Communications Published: 2026-09-07 DOI: https://doi.org/10.1038/s41467-026-77615-9